INOVIO PHARMACEUTICALS, INC. INO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
0/9
Piotroski F — financial health
-85.44
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $65,343 | -$84.9M | — | -$88.9M | $24.1M |
| 2024 | $217,756 | -$107.3M | — | -$104.6M | $68.5M |
| 2023 | $832,010 | -$135.1M | — | -$124.7M | $117.3M |
| 2022 | $10.3M | -$279.8M | — | -$217.2M | $222.4M |
| 2021 | $1.8M | -$303.7M | — | -$216.9M | $399.7M |
| 2020 | $7.4M | -$166.4M | — | -$179.5M | $461.1M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Humeau Laurent | Chief Scientific Officer | 2026-05-20 | Option exercise | 6,027 | — |
| Humeau Laurent | Chief Scientific Officer | 2026-05-20 | Tax withheld | 2,163 | $1.23 |
| Sumner Michael John | Chief Medical Officer | 2026-05-20 | Option exercise | 9,450 | — |
| Sumner Michael John | Chief Medical Officer | 2026-05-20 | Tax withheld | 2,693 | $1.23 |
| KIES PETER | CFO | 2026-05-20 | Option exercise | 8,700 | — |
| KIES PETER | CFO | 2026-05-20 | Tax withheld | 4,688 | $1.23 |
Why these scores methodology →
Piotroski F-score: 0/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -85.44 (distress)
- Working capital / assets 0.235
- Retained earnings / assets -24.427
- EBIT / assets -1.168
- Equity / liabilities 0.48
Source: SEC EDGAR filings · CIK 0001055726 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.